Mode
Text Size
Log in / Sign up
N/A N=548 Randomized Double-blind Diagnostic

North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2

Epilepsy; Seizure · Neuromuscular Diseases · Brain Malformation · Intellectual Disability · Autism Spectrum Disorder

Enrolled (actual)
548
Serious AEs
0.4%
Results posted
May 2025
Primary outcome: Primary: Initial Patient Pediatric Quality of Life (Peds QL) Score — 64.37; 65.83; 60.04; 63.39 score on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Pre-visit prep (Behavioral); usual care + exome seq (Diagnostic_test)
Age
Pediatric, Adult, Older Adult · 0+ yrs
Sex
All
Sponsor
University of North Carolina, Chapel Hill
Primary completion
Sep 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Initial Patient Pediatric Quality of Life (Peds QL) Score
64.37; 65.83; 60.04; 63.39
PRIMARY
Final Patient Pediatric Quality of Life (Peds QL) Score
72.15; 75.74; 71.65; 68.90
PRIMARY
Initial Caregiver QoL Score
50.14; 48.84; 51.30; 47.69
PRIMARY
Intermediate Caregiver QoL Score
51.48; 46.58; 50.66; 50.08
PRIMARY
Final Caregiver QoL Score
53.31; 50.38; 47.41; 47.46
PRIMARY
Post-Clinic Visit 1 Mean Patient Centeredness Score
5.7; 5.7; 5.9; 5.8
PRIMARY
Post-Return of Results Mean Patient Centeredness Score
5.5; 5; 5; 4.8
PRIMARY
Number of Questions Caregiver Asks in Clinic Visit 1
4.36; 2.83
PRIMARY
Number of In-patient Hospital Admissions Among Child Participants 1 Year Prior to Return of Results
0; 3; 4; 2
PRIMARY
Number of In-patient Hospital Admissions Among Child Participants 1 Year After Return of Results
1; 1; 8; 2
PRIMARY
Number of In-patient Hospital Days Among Child Participants 1 Year Prior to Return of Results
0; 13; 22; 1
PRIMARY
Number of In-patient Hospital Days Among Child Participants 1 Year After Return of Results
5; 5; 148; 11
PRIMARY
Number of Long-term Care Admissions Among Child Participants 1 Year Prior to Return of Results
0; 0; 4; 0
PRIMARY
Number of Long-term Care Admissions Among Child Participants 1 Year After Return of Results
0; 0; 3; 0
PRIMARY
Number of Long-term Care Days Among Child Participants 1 Year Prior to Return of Results
0; 0; 29; 0
PRIMARY
Number of Long-term Care Days Among Child Participants 1 Year After Return of Results
0; 0; 17; 0
PRIMARY
Number of ER Visits Among Child Participants 1 Year Prior to Return of Results
15; 25; 35; 35
PRIMARY
Number of ER Visits Among Child Participants 1 Year After Return of Results
10; 29; 20; 23
PRIMARY
Number of Specialists Visits Among Child Participants 1 Year Prior to Return of Results
202; 665; 663; 332
PRIMARY
Number of Specialists Visits Among Child Participants 1 Year After Return of Results
220; 556; 650; 273
SECONDARY
Initial Average Peds QL Score for "Missing School for Not Feeling Well"
70.8; 80.6; 65.5; 73
SECONDARY
Final Average Peds QL Score for "Missing School for Not Feeling Well"
77.1; 82.6; 78.9; 81.3
SECONDARY
Initial Average Peds QL Score for "Missing School for Doctors Visit"
59.7; 65; 54.9; 60
SECONDARY
Final Average Peds QL Score for "Missing School for Doctors Visit"
77.1; 82.6; 78.9; 82.5
SECONDARY
Initial Amount of Work Missed Because of Child's Condition or Treatments Score
2.3; 2.4; 2.5; 2
SECONDARY
Final Amount of Work Missed Because of Child's Condition or Treatments Score
2.3; 2.3; 2.5; 2.6
SECONDARY
Initial Difficulty With Finishing Normal Work (Including Both Work Outside of the Home and Housework) Because of Child's Condition or Treatments Score
2.7; 2.5; 2.7; 2.4
SECONDARY
Intermediate Difficulty With Finishing Normal Work (Including Both Work Outside of the Home and Housework) Because of Child's Condition or Treatments Score
1.9; 2; 2.3; 2.1
SECONDARY
Final Difficulty With Finishing Normal Work (Including Both Work Outside of the Home and Housework) Because of Child's Condition or Treatments Score
2.1; 2.1; 2.1; 2.1
SECONDARY
Percent Concordance of Caregiver and Provider Reports of Genetic or Genomic Test Results
9; 12
SECONDARY
Mean Baseline Self Efficacy Score
4.5; 4.5; 4.6; 4.6
SECONDARY
Mean Pre-Clinic Visit 1 Self Efficacy Score
4.6; 4.4; 4.5; 4.4
SECONDARY
Post-Return of Results Mean FACToR Uncertainty Subscale Score
1.7; 2.4; 2.3; 2.2
SECONDARY
Vital Status at Final f/u
28; 38; 35; 36; 0; 1
SECONDARY
Number of Child Participants With Causes of Death Unrelated to the Study
0; 1; 0; 0

Summary

The "North Carolina Clinical Genomic Evaluation by Next-gen Exome Sequencing, 2 (NCGENES 2)" study is part of a larger consortium project investigating the clinical utility, or net benefit of an intervention on patient and family well-being as well as diagnostic efficacy, management planning, and medical outcomes. A clinical trial will be implemented to compare (1) first-line exome sequencing to usual care and (2) participant pre-visit preparation to no pre-visit preparation. The study will use a randomized controlled design, with 2x2 factorial design, coupled with patient-reported outcomes and comprehensive clinical data collection addressing key outcomes, to determine the net impact of diagnostic results and secondary findings.

Eligibility Criteria

Both children and parents are participants:

Inclusion Criteria

Parents meeting the following criteria:

  • Parent of a child who meets the criteria below
  • At least 18 years old.
  • Must be able to provide informed consent for child and self.
  • Must be fluent in English or Spanish.

Children meeting the following criteria:

  • Infants and children 15 years old or less.
  • Referred for initial evaluation of a possible monogenic disorder OR
  • Seen for evaluation of an undiagnosed disorder in a study-associated clinic.

Exclusion Criteria

Parents:

  • Younger than 18 years old.
  • Unwilling to complete study surveys and other procedures.
  • Have cognitive or other impairments precluding ability to provide giving informed consent.
  • Not fluent in English or Spanish.
  • Unable to attend all clinic visits

Children:

  • Have a known genetic or non-genetic diagnosis (only referred for counseling or management).
  • Medically unstable.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03548779). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search